Determination of the maximum tolerated dose of intranasal sufentanil and midazolam for sedation of gastroscopy using a continual reassessment method

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OPD-17010492

Enrollment

Unknown

Registered

2017-01-20

Start date

2017-01-18

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

digestive disease

Interventions

Case series:intranasal sufentanil (SUF) and midazolam (MID)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: thirty ASA I to II patients, aged 18 to 65 years scheduled for the gastroscopy.

Exclusion criteria

Exclusion criteria: general contraindications for gastroscopy, general contraindications for the use of SUF or MID (i.e. allergic reactions etc.), preexisting hypoxia (oxygen saturation 30, Mallampati classification of III or IV, emergency patients, pregnant patients, respiratory rate =10 /min, history of digestive tract surgery, digestive malformation

Design outcomes

Primary

Measure	Time frame
respiratory rate;oxygen saturation;duration of apnea;	—

Contacts

Public ContactYi Zou

Beijing Friendship Hospital, Capital Medical University

zouyi871123@126.com+86 10-63138780

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026